Treatment of Eosinophilic Annular Erythema: ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Title :
Treatment of Eosinophilic Annular Erythema: Retrospective multicenter study and literature review.
Author(s) :
Chastagner, M. [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Hôpital Edouard Herriot [CHU - HCL]
Shourik, J. [Auteur]
CHU Tenon [AP-HP]
Jachiet, M. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Battistella, M. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Lefevre, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gibier, Jean-Baptiste [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Aubert, H. [Auteur]
Service de dermatologie [Nantes]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Musquer, M. [Auteur]
Descamps, V. [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Deschamps, L. [Auteur]
Chosidow, O. [Auteur]
Hôpital Henri Mondor
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Dynamic Microbiology - EA 7380 [DYNAMIC]
Ortonne, N. [Auteur]
Groh, M. [Auteur]
Hôpital Foch [Suresnes]
Bernier, M. [Auteur]
Jullien, D. [Auteur]
Chasset, F. [Auteur]
Staumont, delphine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bouaziz, J. D. [Auteur]
Kanikatis, J. [Auteur]
Villani, A. P. [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Hôpital Edouard Herriot [CHU - HCL]
Shourik, J. [Auteur]
CHU Tenon [AP-HP]
Jachiet, M. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Service de Dermatologie [AP-HP Hôpital Saint-Louis]
Battistella, M. [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Immunologie humaine, physiopathologie & immunothérapie [HIPI (UMR_S_976 / U976)]
Lefevre, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gibier, Jean-Baptiste [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Aubert, H. [Auteur]
Service de dermatologie [Nantes]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Musquer, M. [Auteur]
Descamps, V. [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Deschamps, L. [Auteur]
Chosidow, O. [Auteur]
Hôpital Henri Mondor
Université Paris-Est Créteil Val-de-Marne - Paris 12 [UPEC UP12]
Dynamic Microbiology - EA 7380 [DYNAMIC]
Ortonne, N. [Auteur]
Groh, M. [Auteur]
Hôpital Foch [Suresnes]
Bernier, M. [Auteur]
Jullien, D. [Auteur]
Chasset, F. [Auteur]
Staumont, delphine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bouaziz, J. D. [Auteur]
Kanikatis, J. [Auteur]
Villani, A. P. [Auteur]
Journal title :
Annales de Dermatologie et de Vénéréologie
Publisher :
Elsevier Masson
Publication date :
2021-11-06
ISSN :
0151-9638
English keyword(s) :
Eosinophilic annular erythema
Eosinophil
Wells syndrome
Eosinophilic cellulitis
Treatment
Eosinophil
Wells syndrome
Eosinophilic cellulitis
Treatment
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
BackgroundEosinophilic annular erythema (EAE) is a rare eosinophil-related skin disease which typically manifests with annular erythematous plaques and severe pruritus. Besides the diagnosis, the treatment of EAE is ...
Show more >BackgroundEosinophilic annular erythema (EAE) is a rare eosinophil-related skin disease which typically manifests with annular erythematous plaques and severe pruritus. Besides the diagnosis, the treatment of EAE is challenging since relevant published data are sparse.MethodsThe aim of this study was to assess the underlying diseases, treatments and outcomes of patients with EAE. To this end, we conducted a retrospective multicenter study and a systematic review of the MEDLINE database.ResultsWe included 18 patients with EAE followed in 8 centers. The MEDLINE database search yielded 37 relevant publications reporting 55 cases of EAE with 106 treatment sequences. The most common and efficient treatments included topical or systemic corticosteroids, hydroxychloroquine and dapsone. In refractory patients, a combination of systemic corticosteroids with hydroxychloroquine was associated with 88% of complete clinical response.DiscussionTo improve the management of EAE patients, we discuss the following treatment strategy: in topical steroid-resistant patients, hydroxychloroquine can be given as first-line systemic treatment. Dapsone, hydroxychloroquine or systemic corticosteroids are second-line options to consider. Last, monoclonal antibodies or JAK inhibitors targeting type 2 inflammation could represent promising last-resort options in refractory patients.Show less >
Show more >BackgroundEosinophilic annular erythema (EAE) is a rare eosinophil-related skin disease which typically manifests with annular erythematous plaques and severe pruritus. Besides the diagnosis, the treatment of EAE is challenging since relevant published data are sparse.MethodsThe aim of this study was to assess the underlying diseases, treatments and outcomes of patients with EAE. To this end, we conducted a retrospective multicenter study and a systematic review of the MEDLINE database.ResultsWe included 18 patients with EAE followed in 8 centers. The MEDLINE database search yielded 37 relevant publications reporting 55 cases of EAE with 106 treatment sequences. The most common and efficient treatments included topical or systemic corticosteroids, hydroxychloroquine and dapsone. In refractory patients, a combination of systemic corticosteroids with hydroxychloroquine was associated with 88% of complete clinical response.DiscussionTo improve the management of EAE patients, we discuss the following treatment strategy: in topical steroid-resistant patients, hydroxychloroquine can be given as first-line systemic treatment. Dapsone, hydroxychloroquine or systemic corticosteroids are second-line options to consider. Last, monoclonal antibodies or JAK inhibitors targeting type 2 inflammation could represent promising last-resort options in refractory patients.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Collections :
Source :
Files
- document
- Open access
- Access the document
- S0151963821000909.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- S0151963821000909.pdf
- Open access
- Access the document